Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141971 · ClinicalTrials.gov registry record
Down Syndrome Biomarker Initiative (DSBI)
A clinical trial of Alzheimers Disease and Down Syndrome, sponsored by Michael Rafii.
- Completed
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT02141971 is a study of Alzheimers Disease and Down Syndrome that has completed, run by Michael Rafii. The registered enrollment target is 12 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02141971, a study of Alzheimers Disease and Down Syndrome, has completed, sponsored by Michael Rafii.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Non-randomized natural history study involving 12 subjects with Down Syndrome, who are aged 30-60 years old. This study will observe 3 different groups: four non-demented subjects between ages 30-40 years old, four non-demented subjects between ages 40-50 years old, and four demented subjects 50-60 years old. Currently available longitudinal data in DS suggest a high rate of transition to dementia from the late 40s through the early 50s of these individuals. This, together with the universal presence of plaques in DS by their mid 40s makes this age range ideal for studying the development of AD.
Conditions Studied
Study Locations (1)
California
- University of California, San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-06-01 |
| Est. Completion | 2017-04-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02141971
The ClinicalTrials.gov registry entry for NCT02141971 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (100% lower). The listed sponsor is Michael Rafii, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alzheimers Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02141971 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02141971 about?
NCT02141971 is a clinical study titled "Down Syndrome Biomarker Initiative (DSBI)". Non-randomized natural history study involving 12 subjects with Down Syndrome, who are aged 30-60 years old. This study will observe 3 different groups: four non-demented subjects between ages 30-40 years old, four non-demented subjects between ages 40-50 years old, and four demented subjects 50-60 ...
What is the current status of trial NCT02141971?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2013-06-01. Estimated completion is 2017-04-15.
What conditions does trial NCT02141971 study?
This clinical trial studies the following conditions: Alzheimers Disease, Down Syndrome.
Who is sponsoring clinical trial NCT02141971?
This trial is sponsored by Michael Rafii, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02141971 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
University of Central Florida Music Study
RECRUITING · NA
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.